Expanding the genetic landscape of endometriosis: Integrative -omics analyses implicate key genes and pathways in a multi-ancestry study of over one million women

Authors and Affiliations

Corresponding Author: Shefali Setia-Verma

Lindsay A Guare[1], Jagyashila Das[1], Lannawill Caruth[1], Ananya Rajagopalan[2], Alexis T. Akerele[3], Ben M Brumpton[4], Tzu-Ting Chen[5], Leah Kottyan[6], Yen-Feng Lin[5], Elisa Moreno[4], Ashley J Mulford[7], Marija Simona Dombrovska[8], Yuan Luo[9], Vita Rovite[8], Alan R Sanders[7], Craig Teerlink[10], Danielle Candelieri[10], Noemie Elhadad[11], Andrew Hill[12], Gail P. Jarvik[13], James Jaworski[14], Julie Lynch[10], Shinichi Namba[15], Yukinori Okada[15], Yue Shi[16], Yuya Shirai[17], Jonathan Shortt[12], Wei-Qi Wei[18], Chunhua Weng[11], Yuji Yamamoto[17], Penn Medicine Biobank, Regeneron Genetics Center, Global Biobank Meta-analysis Initiative, Sinead Chapman[16], Wei Zhou[16], Todd Edwards[19], Suneeta Senapati[20], Digna R. Velez Edwards[21], Shefali Setia-Verma[1]

[1]Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, United States, [2]Genomics and Computational Biology, University of Pennsylvania, Philadelphia, PA, United States, [3]Division of Quantitative Science, Department of Obstetrics and Gynecology, Department of Microbiology, Immunology, and Physiology, Vanderbilt University Medical Center, and Meharry Medical College, Nashville, TN, United States, [4]HUNT Center for Molecular and Clinical Epidemiology, Norwegian University of Science and Technology, Trondheim,

Norway, [5]Center for Neuropsychiatric Research, National Health Research Institutes, Maoli

County, Taiwan, [6]Cincinnati Children's Hospital Medical Center, Cincinatti, OH, United

States, [7]Endeavor Health, Evanston, IL, United States, [8]Latvian Biomedical Research and Study

Centre, Riga, Latvia, [9]Feinberg School of Medicine, Northwestern University, Chicago, IL, United

States, [10]VA Informatics and Computing Infrastructure, VA Salt Lake City Healthcare System,

Salte Lake City, UT, United States, [11]Biomedical Informatics, Columbia University, New York City,

NY, United States, [12]Colorado for Precision Medicine, Aurora, CO, United States, [13]Division of

Medical Genetics, University of Washington, Seattle, WA, United States, [14]Division of

Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville,

Tennessee, United States, [15]Genome Informatics, The University of Tokyo, Tokyo, Japan, [16]Broad

Institute, Cambridge, MA, United States, [17]Statistical Genetics, Osaka University, Suita, Osaka,

Japan, [18]Biomedical Informatics, Vanderbilt University, Nashville, TN, United States, [19]Division of

Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN,

United States, [20]Division of Reproductive Endocrinology and Infertility, Department of Obstetrics

and Gynecology, Hospital of the University of Pennsylvania, Philadelphia, PA, United

States, [21]Division of Quantitative Science, Department of Obstetrics and Gynecology,

Department of Microbiology, Immunology, and Physiology, Vanderbilt University Medical

Center, Nashville, Tennessee, United States

Abstract

We report the findings of a genome-wide association study (GWAS) meta-analysis of endometriosis across 14 biobanks worldwide, including 32% non-European patient participants, as part of the Global Biobank Meta-Analysis Initiative (GBMI). Out of 58 total loci (29 previously unreported), the largest meta-analysis accounted for 46 (20 previously unreported). We detected the first genome-wide significant loci (*2p13.3* and *20q13.2*) uniquely driven by the African-ancestry meta-analysis. Our imaging- and surgery-confirmed phenotypes yielded six additional previously unreported loci. Leveraging our large and diverse study population, we observed SNP heritability estimates of 9-13% for all ancestry groups, and 13 loci had at least one variant in the credible set after fine-mapping. Investigating the complex array of endometriosis comorbidities and risk factors revealed 135 genetically correlated phenotypes and 95 with evidence of vertical pleiotropy, including triglycerides and anxiety disorders. We prioritized 35 disease-relevant cellular contexts from the endometrial cell atlas and found 322 examples of differentially expressed genes in cells from donors with endometriosis. Further high-throughput multi-omic analyses implicated a total of 282 genes in endometriosis pathogenesis. Our diverse, comprehensive GWASs, with downstream analyses spanning molecular to phenotypic scales, provide detailed evidence for aspects of endometriosis including the role of immune cell types, Wnt signaling, and cellular proliferation. These interconnected pathways and risk factors underscore the complex, multi-faceted etiology of endometriosis, suggesting multiple targets for precise and effective therapeutic interventions.

Introduction

Endometriosis, a debilitating condition characterized by the growth of endometrial-like tissues outside of the uterus affects approximately 10% of women of reproductive age worldwide[1,2]. The precise mechanisms of these lesions are presently unknown. Endometriosis is incurable, leaving patients to manage severe pain[3] and cope with fertility challenges[4]. Despite its prevalence and impact, the etiology of endometriosis remains poorly understood, hampering efforts to develop effective diagnostic tools and targeted treatments.

Genome-wide association studies (GWASs) have been an important tool for suggesting candidate genes and pathways linked with endometriosis[5–7]. GWASs for endometriosis have uncovered over 40 loci associated with endometriosis risk. However, like most GWASs historically, the previous endometriosis studies have primarily included European ancestry populations and at a smaller scale, East-Asian[8]. While the broad sense heritability of endometriosis has been estimated as 47% via a twin study[9], previous endometriosis GWASs have only explained about 7% of phenotypic variance with common variants[5,6] and have fallen short in elucidating the full spectrum of its pathophysiology.

The advent of large-scale biobanks has revolutionized genetic research, offering unique opportunities to conduct well-powered studies across diverse populations[10–13]. As more diverse genomic datasets become available like the Penn Medicine Biobank (PMBB)[14], the All of Us Research Program (AOU)[15], and the Million Veterans Program (MVP)[16], they enhance the discovery of trait loci through increased statistical power and variation enriched in non-European populations[10]. A worldwide consortium of genomic researchers, the Global Biobank Meta-Analysis Initiative (GBMI), was established to facilitate collaboration in GWAS studies on

unprecedented scales. In this study, we at the PMBB have collaborated with 12 other biobanks

across several countries[15,17–27] and incorporated publicly-available summary statistics from

FinnGen, totaling 14 global datasets. These resources not only enhance statistical power to

detect novel associations but also provide rich phenotypic data, enabling more refined analyses.

Moreover, the inclusion of diverse ancestries in genetic studies is crucial to aid in fine-mapping

and for improving the generalizability of findings and addressing health disparities. This is

particularly pertinent for endometriosis, where significant variations in prevalence and clinical

presentation have been observed across different ethnic groups[28].

Beyond GWAS, there are many methods which can be employed *in silico* to investigate

other elements of the central dogma, providing further validation of GWAS loci and discovery of

additional disease-associated genes. Recent advances in multi-omics technologies have further

expanded our ability to translate genetic associations into biological insights. Integration of

GWAS results with multi-omic QTL and single-cell datasets using methods such as imputed

association studies and Mendelian randomization allows for a more comprehensive

understanding of disease mechanisms, potentially identifying novel therapeutic targets and

biomarkers. For endometriosis, where the interplay between genetic predisposition and complex

tissue-specific processes is central, integrative approaches are especially valuable. Given these

considerations, there is a critical need for a large-scale, ancestrally diverse GWAS of

endometriosis that incorporates rigorous phenotyping and leverages multi-omics data to provide

a more complete picture of the disease's genetic landscape and underlying biology.

Here, we present the results of a large-scale GWAS meta-analysis that significantly

advances our understanding of endometriosis pathophysiology. Our study encompasses a

diverse cohort from 14 biobanks worldwide, with over 30% non-European participants,

enhancing the generalizability of our findings. We employed a comprehensive phenotyping

approach, including not only a wide spectrum of endometriosis presentations but also surgically

confirmed and procedure-validated (surgery or imaging) phenotypes. This robust phenotyping

strategy enables greater resolution when examining the genetic architecture of endometriosis.

Through high-throughput exploration of pleiotropy and integrative multi-omics analyses, we

have explored numerous layers of endometriosis pathogenesis. These findings provide

unprecedented insights into the risk factors and molecular mechanisms driving this complex

disorder, paving the way for improved diagnostics and targeted therapeutic interventions.

Results

EHR-Based Phenotyping of Endometriosis in Genetically Diverse Datasets

Of the six case-control definitions (W - Wide, Wex - Wide excluding adenomyosis, PCN.v2 and

PCN.v2 - Procedure-Confirmed Narrow [vs (1) all and (2) confirmed controls], and SCN.v1 and

SCN.v2 - Surgically-Confirmed Narrow [vs (1) all and (2) confirmed controls]), the largest

phenotype, W, comprised 1,063,657 women (31.9% non-EUR), including 50,265 cases. The Wex

phenotype, for which several biobanks were omitted, had a total sample size of 615,050 (N_{cases} =

12,262). Sample sizes for the PCN and SCN phenotypes were smaller (Table 1), with summary

statistics included from only nine of the 14 biobanks (Supplementary Table 1).

Table 1: All GWAS meta-analysis sample sizes. All six phenotypes had a multi-ancestry meta-analysis as well as single-
ancestry meta-analyses for AFR, AMR, CSA+SAS, EAS, and EUR. There were not enough CSA+SAS or EAS studies to
conduct meta-analyses for all the narrow phenotypes. Phenotype abbreviations: W = wide, Wex = wide excluding
adenomyosis, PCN = procedure-confirmed narrow, SCN = surgically-confirmed narrow, .v1 = versus all controls, .v2
= versus confirmed controls. Ancestry abbreviations: AFR = African, AMR = admixed American, CSA = central/south
Asian, SAS = south Asian, EAS = east Asian, EUR = European.

Phenotype	Ancestry	N	Cases	Prevalence
W	AFR	96,012	4,289	4.47%
	AMR	67,335	2,136	3.17%
	CSA+SAS	8,164	259	3.17%
	EAS	168,209	7,833	4.66%
	EUR	723,937	35,748	4.94%
	META	1,063,657	50,265	4.73%
Wex	AFR	92,202	1,575	1.71%
	AMR	66,219	1,020	1.54%
	CSA+SAS	5,066	62	1.22%
	EAS	86,667	1,584	1.83%
	EUR	364,896	8,021	2.20%
	META	615,050	12,262	1.99%
PCN.v1	AFR	70,959	1,152	1.62%
	AMR	58,802	750	1.28%
	EAS	78,999	155	0.20%
	EUR	317,481	4,053	1.28%
	META	526,241	6,110	1.16%
PCN.v2	AFR	12,958	1,152	8.89%
	AMR	9,472	750	7.92%
	EAS	1,539	155	10.07%
	EUR	56,134	4,053	7.22%
	META	80,103	6,110	7.63%
SCN.v1	AFR	70,308	501	0.71%
	AMR	58,477	425	0.73%
	EUR	284,932	2,573	0.90%
	META	413,717	3,499	0.85%
SCN.v2	AFR	1,912	501	26.20%
	AMR	2,291	425	18.55%
	EUR	14,147	2,573	18.19%
	META	18,350	3,499	19.07%

Across the 11 meta-analyses (six multi-ancestry meta-analyses for the different phenotype

definitions plus five single-ancestry W meta-analyses), we identified 3,165 unique genome-wide

significant variants ($P < 5 \times 10^{-8}$), corresponding to 5,049 associations (Supplementary Table 2).

These associations were aggregated into 249 linkage disequilibrium (LD) clumps (Supplementary

Table 3), which further merged into 104 distinct loci across the 11 meta-analyses (Supplementary

Table 4). When we consolidate loci shared between meta-analyses, we arrive at 58 total loci.

Study-wide loci shown in Figure 1 are labeled with the most significant corresponding gene from

the downstream multi-omic analyses (described below) or the cytoband (Supplementary Table

5). The largest analysis (multi-ancestry W phenotype) resulted in 46 loci associated with

endometriosis. Besides those, there were three EUR-specific W loci (*GRB14, ZNF536,* and *CHD6*),

totaling 49 W loci annotated in Figure 1a. The two AFR and two of the seven EAS W loci were

unique among the single-ancestry GWASs but all were overlapping with signals from the multi-

ancestry meta-analyses; meanwhile, the AMR and CSA+SAS W GWASs did not yield any genome-

wide significant loci. Of the 49 unique W loci, 26 of the lead SNPs were in LD ($R^2 > 0.1$) with the

lead SNPs reported in *Rahmioglu et al, 2023*, and an additional three were found within 1 Mb of

the previous lead SNPs[6]. The associations between endometriosis and the 20 remaining W loci

are reported here for the first time.

Figure 1: Overview of 11 GWAS meta-analysis results. a) Top left: overlayed Manhattan plots for the five Wide

endometriosis phenotype GWASs (multi-ancestry + four single-ancestries). All significant loci are annotated with

black text highlighting the previously unreported hits. b) Top right: LD-score regression (using LDSC) heritability

estimates for the W GWASs; AMR is excluded because there was not sufficient sample size to use LDSC. c) Bottom

left: Overlayed Manhattan plots for the five multi-ancestry GWASs for the other phenotypes. d) Bottom right:

volcano plot highlighting variants with an absolute log-odds effect size > 0.1, colored by ancestry group. Phenotype

abbreviations: W = wide, Wex = wide excluding adenomyosis, PCN = procedure-confirmed narrow, SCN = surgically-

confirmed narrow, .v1 = versus all controls, .v2 = versus confirmed controls. Ancestry abbreviations: AFR = African,

AMR = admixed American, EAS = east Asian, EUR = European.

Liability scale genome-wide SNP heritability estimates and standard errors (h^2_{lia}) from the

W single-ancestry meta-analyses are shown in Figure 1b. The h^2 estimates and their standard

errors were: 0.133 (0.054) for AFR, 0.106 (0.021) for EAS, and 0.108 (0.008) for EUR. Heritability

estimates (via the LD-score regression tool, LDSC) for all analyses are provided in Supplementary

Table 6. Partitioned LD-score regression (Supplementary Table 7) attributed significant

proportions of the phenotypic variance to uterine-specific active enhancers (epigenome map

state called "EnhA2") in EAS ($prop_{h2}$ = 33%, enrichment = 26-fold, $P_{prop\ h2}$ = 1.2 x 10^{-3}) and EUR

($prop_{h2}$ = 20%, enrichment = 15-fold, $P_{prop\ h2}$ = 6.6 x 10^{-4}). Two others explained significant

portions of the heritability: ncRNA_gene (non-coding RNA genes) in EAS ($prop_{h2}$ = 21%,

enrichment = 1.4-fold, $P_{\text{prop h2}}$ = 2.6 x 10^{-3}) and TssFlnk (regions flanking transcription start sites)

in EUR (prop$_{\text{h2}}$ = 7%, enrichment = 1.3-fold, $P_{\text{prop h2}}$ = 0.031). Cross-ancestry genetic correlation

estimates with Popcorn were under-powered, with none being significantly different from one.

The strongest estimate was between EAS and EUR: ρ_{gi} = 0.76, P = 0.063 (all genetic impact

correlation estimates are available in Supplementary Table 8).

Precise Phenotype Analyses Replicate Known Loci and Reveal Additional Loci

Across the remaining phenotype meta-analyses, we identified 14 significant loci: eight with Wex,

three with PCN.v1, one with both PCN.v1 and SCN.v1, and two with PCN.v2. Three of the eight

loci associated with Wex in the multi-ancestry analysis replicate previously reported signals,

while the other five are previously unreported: *1q12.13, FSHR:1, 4q35.2, SCNN1A,* and *TCEA2*. All

six loci associated with the narrow phenotypes are previously unreported (Figure 1c). The

surgically-confirmed phenotype associations displayed the most extreme effect sizes (Figure 1d),

including *21q22.13* (rs186666195:T OR$_{\text{SCN.v1}}$ = 5.23 and OR$_{\text{PCN.v1}}$ = 3.65) and *13q22.1*

(rs189908888:T OR$_{\text{PCN.v2}}$ = 2.48). The liability scale heritability captured by the EUR Wex GWAS

was 0.096 (0.0018). Heritability estimates for the remaining narrow phenotypes were non-

significant and are provided in Supplementary Table 6. None of the partitioned heritability

estimates for the Wex and narrow phenotypes (EUR-only) reached significance (Supplementary

Table 7).

Fine-Mapping to Detect Causal Variants at GWAS Loci

To characterize shared and population-specific putative causal variants, we conducted statistical

fine-mapping (See Methods) on all genome-wide significant regions from multi-population meta-

analyses, totaling 63 significant loci in five of the six studies (the SCN.v2 meta-analysis yielded no

genome-wide significant results). Among these, 13 loci contained at least one variant with

posterior inclusion probability (PIP) greater than 0.5, corresponding to 85 unique causal variants

with strong evidence for causality (Supplementary Table 9). The cross-ancestry fine-mapping

analyses computed PIPs for each variant across all combinations of ancestry groups included in

the overall study. We identify credible sets (CS) for the 13 distinct loci associated with

endometriosis as reported in Table 2.

Table 2: Credible sets of multi-ancestry GWAS loci. nine are for the W phenotype, two are for Wex, one is for PCN.v1,
and one for PCN.v2. An "X" in the ancestry population columns denote whether that ancestry group was used for
detecting any SNPs in the credible set (PIP > 0.5). Locus names match Figure 1. Phenotype abbreviations: W = wide,
Wex = wide excluding adenomyosis, PCN = procedure-confirmed narrow, .v1 = versus all controls, .v2 = versus
confirmed controls. Ancestry abbreviations: AFR = African, AMR = admixed American, EAS = east Asian, EUR =
European, SAS = south Asian.

Phenotype	Locus	# CS	AFR	AMR	EAS	EUR	SAS	Credible Set
W	WNT4	1			X	X		rs2807365
W	1p13.2	4			X	X	X	rs12030576, rs2982742, rs61810746, rs6328
W	GREB1	3		X	X	X		rs7578132, rs10929759, rs59129126
W	FSHR:2	2		X	X	X	X	rs1504175, rs1504188
W	CD109	1	X	X		X		rs77740740
W	7p15.2	1	X		X	X		rs1451385
W	7p12.3	2		X	X	X		rs10479868, rs11975261
W	ADK	2		X	X	X	X	rs4268450, rs11001059
W	DTD1	4			X	X	X	rs6081248, rs6081313, rs34478401, rs6045577
Wex	FSHR:1	1		X		X		rs2300440
Wex	9p21.3:2	3	X		X	X		rs1333054, rs10965274, rs10811669
PCN.v1	19q12	7	X			X		rs56124241, rs10411368, rs12981956, rs59841764, rs57255653, rs12973006, rs12972676
PCN.v2	MEGF6	1		X		X		rs76419782

Of the 13 loci with at least one variant in the credible set, nine were from the W multi-

population meta-analysis, two were from Wex, and there was one each from PCN.v1 and PCN.v2.

Twelve of the credible sets included variants detectable in part due to the incorporation of

additional genetic ancestry groups (AMR, AFR, and SAS) previously absent from analyses. In

particular, two loci (*FSHR:2* and *ADK.)* derived their credible sets from incorporating four of the

five ancestry groups. All PIPs from MESuSiE are available in Supplementary Table 9.

GWAS Variant-Set Gene Enrichment Analyses

From 11 meta-analyses, we identified 78 associations with 46 unique gene regions that were

enriched for significant GWAS variants. Eleven gene regions from MAGMA did not overlap with

significant GWAS loci, of which 9 were detected by W analyses. Two of the 9 were significant in

both the META and EUR wide phenotype GWASs: *CCHCR1* and *KCTD13*. The other two non-GWAS

significant MAGMA hits were for the Wex (*GLB1L3*, P = 3.66 x 10^{-7}) and PCN.v1 (*LRRC2*, P = 3.40

x 10^{-7}) phenotypes. All significant MAGMA results are reported in Supplementary Table 10.

Exploring Pleiotropy via Genetic Correlation and Mendelian Randomization

Out of 3,065 genetic correlation tests spanning complex trait GWASs from the UK Biobank

(UKBB) phenome, the All of Us (AOU) phenome, microbiome, and partial proteome datasets, 890

traits were nominated for bidirectional Mendelian randomization analysis. A total of 135

phenotypes showed significant genetic correlation with endometriosis at a Bonferroni-corrected

threshold of P < 1.63 x 10^{-5}, including age at first live birth (rg = -0.24), sleeplessness/insomnia (rg

= 0.19), headache (rg = 0.30), and antidepressants prescription (rg = 0.39). Evidence for vertical

pleiotropy was observed in 95 exposure-outcome pairs, including associations suggestive of

endometriosis contributing to risk of hyperlipidemia, prescription of antacids, and reduced levels

of Apolipoprotein F and *Bifidobacteriaceae*. Nominated genetic correlation traits and their MR

results are shown in Figure 2. Detailed results of the analyses are provided in Supplementary

Tables 11 and 12 for genetic correlation and MR, respectively.

Figure 2: Genetic correlation (GC) and Mendelian randomization (MR) analyses. Each scatter point, colored by
category, represents a GC estimate for which the p-value was less than 0.05. Filled shapes indicate a Bonferroni-
significant GC value. Triangles indicate significant causal relationships detected by MR. Selected results are
highlighted with boxes. A color fill corresponds to a significant GC estimate whereas a colored outline did not reach
multiple testing GC significance. Bold text in the annotation boxes indicates a significant MR pair.

Identifying Disease-Relevant Cell Types and Crucial Genes

We prioritized 34 cellular contexts (cell type – menstrual stage pairs) with significant regression

coefficients (P < 2.08 x 10⁻⁴) for comparison of gene expression among the top MAGMA-identified

genes (Figure 3). Regression results of endometriosis status on single cell disease risk score

(scDRS) value across all tested cell type-menstrual stage pairs are provided in Supplementary

Table 13.

Figure 3: Single cell analyses – disease relevance scores (scDRSs) and differential gene expression. The left warm-
colored panels show the odd-scale regression coefficients when comparing cells from donors with endometriosis to
donors without endometriosis. Each row is annotated with the menstrual stage, cell type, and data type. The rows
are ordered by cell type lineage. The right cool-colored panels show the results of two-sided t-tests comparing the
gene expression of the top MAGMA genes, with significant tests represented by upward tringles for overexpression
and downward triangles for underexpression.

Of the 34 cell contexts with significant regression effect estimates, 14 were derived from

donors in the "hormones" menstrual phase, five from the proliferative phase, and 15 from the

secretory phase. These contexts spanned all four cellular lineage groups: three endothelial, eight

epithelial, ten immune, and 13 mesenchymal. The largest regression coefficient was observed in

venous cells from donors on hormones (odds-scale coefficient = 2.34, P = 1.02 x 10^{-18}). The most

statistically robust signal emerged in endometrial stromal cells sampled during the proliferative

phase (odds-scale coefficient = 1.40, P = 1.58 x 10^{-231}). Among the genes driving the performance

of each regression model, *ESR1* was most frequently differentially expressed, reaching

significance in 24 of the cellular contexts, with 19 of those being overexpression and 5

demonstrating depletion. *GREB1* was the most consistently upregulated gene (23 contexts: 10

hormones, 10 secretory, and 3 proliferative), whereas *ADK* and *ZBTB2* were the most consistently

downregulated (7 contexts each). Decidualized stromal cells from the mid-secretory phase

exhibited the largest number of differentially expressed genes overall (21 genes: 13 upregulated

and 8 downregulated).

Eight differentially expressed genes overlap with seven of GWAS loci that had not been

previously associated with endometriosis. Gene expression results across all cell type–menstrual

stage contexts are provided in Supplementary Table 14. *FSHR* demonstrated strong

overexpression in two nucleus types: proliferative-phase SOX9 functionalis II (11.8-fold, P = 1.79

x 10^{-7}) and late decidualized stromal from donors on hormones (11.0-fold, P = 1.36 x 10^{-22}).

Menstrual-stage-dependent association directions were observed for *EEFSEC*; in particular,

uterine natural killer nuclei had a higher expression of *EEFSEC* gene in donors taking exogenous

hormones (1.52-fold, P = 3.5 x 10^{-12}), but in the same type of nuclei in the secretory phase, it was

reduced (0.702-fold, P = 1.50 x 10^{-9}). Two immune nucleus types from donors taking hormones

showed high enrichment of *GMNC*, lymphoid (7.99-fold, P = 4.1 x 10^{-8}) and myeloid (6.02-fold, P

= 2.45 x 10^{-5}). Relative expression of *RSPO3* within stromal cells peaked during the early secretory

phase (1.78-fold, P = 1.65 x 10^{-14}) relative to the proliferative stage (1.17-fold, P = 1.79 x 10^{-8}) and

the mid secretory phase (0.325-fold, P = 5.00 x 10^{-133}). Two genes from the *ADK* locus, *AP3M1*

and *ADK* shared associations with two cellular contexts, late-secretory decidualized stromal cells

and pre-luminal secretory cells. *DTD1* was differentially expressed in five stromal cell contexts,

four positively (early, mid, late decidualized and proliferative nondecidualized) and one

negatively (nondecidualized secretory-stage stromal cells: 0.91-fold, P = 3.84 x 10^{-13}). Six of the

ten *NOL4L*-associated contexts involved nucleus types from donors exposed to exogenous

hormones, all demonstrating positive association (1.46- to 2.72-fold, P < 1.36 x 10^{-5}).

Post-GWAS Multi-Omic Analyses Fuel Pathway Identification

To identify associations between endometriosis and additional layers of the central dogma and

beyond (p - proteome, s - splice-ome, e - transcriptome, m - methylome, and ed - RNA edit-ome),

we performed imputed association studies (xWAS) and QTL-wide summary-based Mendelian

randomization (SMR), inputting the eleven GWASs' summary statistics (See Methods). In total,

xWAS implicated 54 unique molecular phenotypes, including 2 proteins, 73 introns, and 35

transcripts (Supplementary Table 15). Causal relationships involving 235 unique genes were

identified by SMR, represented by 1 pQTL, 57 sQTLs, 34 eQTLs, 353 mQTLs, and 6 edQTLs (Figure

4; Supplementary Table 16).

Figure 4: xQTL summary-based Mendelian randomization (xSMR) and PrediXcan imputed "x"ome-wide association
study (xWAS) results across four tissue types and five -omic layers: a) proteome, b) splice-ome, c) transcriptome, d)

methylome, and e) RNA edit-ome. The p-value thresholds were adjusted for the numbers of tests per analysis (count
of sites per combination of GWAS – QTL dataset). The number of genes displayed on each panel is limited to the 35
most significant. Genes annotated in gray overlap with MAGMA genes whereas genes annotated in black do not.
Triangles point upward for a positive effect and down for a negative effect.

Of the 266 genes implicated by xQTL summary-based Mendelian randomization (xSMR)

and PrediXcan imputed "x"ome-wide association studies (xWAS), 32 overlapped with genome-

level associations identified by MAGMA. Above and beyond the GWAS-related genes, pSMR and

PWAS detected one protein, sSMR and SWAS identified introns at 33 genes, eSMR and TWAS

revealed 44 genes, mSMR identified methylation sites at 164 genes, and edSMR implicated RNA

editing sites at three genes. Several genes were supported by multiple layers of evidence, notably

KDR and RSPO3 which exhibited associations across MAGMA, the proteome, and the

transcriptome. In contrast, we detected associations with CCDC88B and WASHC3 in both the

splice-ome and transcriptome, but no corresponding associations were detected at the genome-

level by MAGMA.

The only pSMR signal without significant heterogeneity was the protein TIM-4, with a

positive association across three GWASs: AMR W (B = 0.594, P_{SMR} = 3.26 x 10^{-5}), META PCN.v1 (B

= 0.402, P_{SMR} = 1.48 x 10^{-6}), and META PCN.v2 (B = 0.384, P_{SMR} = 1.27 x 10^{-5}). VCL was the only

gene in the intersection of the sSMR with SWAS results, represented by three distinct splicing

events with associations across all four tissues, chr10:74109156-74111909 (B = -0.0803, P_{SMR} =

2.81 x 10^{-7}, P_{SWAS} = 1.32 x 10^{-9}), chr10:74109156-74114184 (B = 0.0692, P_{SMR} = 8.37 x 10^{-8}, P_{SWAS} =

2.93 x 10^{-9}), and chr10:74112112-74114184 (B = -0.0735, P_{SMR} = 1.51 x 10^{-6}, P_{SWAS} = 4.52 x 10^{-8}).

The most-replicated transcriptome result was the association of endometriosis with reduced

EEFSEC expression in both whole blood and cultured fibroblast cells (min P_{SMR} = 5.51 x 10^{-7} and

min P_{TWAS} = 4.31 x 10^{-11}). The gene with the highest number of significant CpG sites (12) from

mSMR was *ESR1*. Methylation sites from intron 1 had positive SMR coefficients (highest B = 0.197,

P_{SMR} = 2.16 x 10^{-7}; probe cg04211581) whereas methylation sites from intron 2 had negative SMR

coefficients (lowest B = -0.283, P_{SMR} = 3.02 x 10^{-7}; probe cg24764793). Of the six significant RNA-

editing sites, the most robust site (chr3:156540497) showed six significant edSMR associations

across three tissues. This site in the *SSR3* gene demonstrated stronger effect sizes with the SCN.v1

(surgically-confirmed) GWAS than with the wide phenotype (B = -0.0769, P_{SMR} = 2.61 x 10^{-5} for

fibroblast cells and B = -0.0731, P_{SMR} = 3.06 x 10^{-5} for uterus).

Including genomic signals from MAGMA, we identified 282 genes across six -omics types,

each supported by respective biological evidence of endometriosis association. We performed

chi-squared tests for this gene list with gene sets curated by MSIGDB (Supplementary Table 17)

and identified several significant groups. From the Biocarta category of gene sets, there was only

one gene set identified, the CREM pathway (P = 1.66 x 10^{-7}). Top regulatory gene sets include

target genes of *MIR128_1_5P* (P = 9.68 x 10^{-11}), *ZNF92* (P = 7.70 x 10^{-10}), and *MIR124_5P* (P = 1.78

x 10^{-7}). The most significant biological processes from the GO (gene ontology) were sinoatrial

node cell development (P = 3.44 x 10^{-8}), mitochondrial fission (P = 6.99 x 10^{-8}), and regulation of

DNA ligation (P = 6.08 x 10^{-7}). The strongest hit from the GO molecular function category was

Wnt protein binding (P = 5.89 x 10^{-10}).

Discussion

We report the most diverse GWAS of over a million women for endometriosis to date

incorporating participants from 14 biobanks across the world. Out of 58 loci from 11 meta-

analyses, 29 are previously unreported (20 W, 3 Wex, 6 PCN and SCN) while 26 are in LD with (R^2

> 0.1) and three more are proximal to (1 Mb) known signals. We have specified biological

evidence of the genes or proteins relevant to 15 of the previously unreported loci. In addition to

specifying 85 putative causal variants, we also detected shared genetic architecture between

endometriosis and 135 complex polygenic phenotypes. Then, with the integration of five

additional -omics layers, we have implicated a total of 282 genes associated with endometriosis.

Our ancestry-stratified meta-analyses revealed a consistent observed SNP heritability of

9-13% for endometriosis for four studied genetic ancestry populations with sufficient size (AFR,

AMR, EAS, and EUR), which is higher than previously observed SNP heritability of 7% based on a

majority-European population[6]. The higher and more consistent heritability we observed can be

attributed to the unprecedented scale and diversity of our study cohort. The previous GWASs

have not included any African-ancestry (AFR), Admixed-American-ancestry (AMR), or

Central/South Asian (CSA+SAS) populations, which were essential in the computation of 12 / 13

(92%) credible sets in our fine-mapping analysis. We detected two multi-ancestry loci whose

associations were driven by the AFR cohorts (they were only also significant in the AFR meta-

analysis): *2p13.3* and *20q13.2*. By incorporating biobanks from various regions and ancestry

backgrounds worldwide, we were able to capture a more comprehensive genetic landscape of

endometriosis.

Given that diagnosis codes from the EHR can lack sensitivity for accurately phenotyping

endometriosis[29], we employed narrow phenotyping algorithms which incorporated procedure

codes (surgical and imaging). Despite the diminished sample sizes, there were still 13 genome-

wide significant loci: eight for Wex, four for PCN.v1, two for PCN.v2, and one for SCN.v1 (*21q22.13*

is shared between PCN.v1 and SCN.v1). Four of the loci from the more precise phenotypes were

successfully fine-mapped, including *FSHR:1* for Wex and *19q12* for PCN.v1, with one and seven

putative causal variants in their credible sets, respectively. MAGMA detected regional

associations with three genes (*LRRC2* with PCN.v1 and *GLB1L3* and *TCEA2* with Wex) that were

not detected in the largest GWAS. Leveraging multi-modal EHR data for more precise

phenotyping enhanced our ability to refine and validate genetic associations and uncover deeper

biological insights.

Endometriosis has multifaceted risk factors and complex clinical presentations with a

wide range of comorbidities and concomitant conditions. We explored genetic correlation and

pleiotropy with endometriosis on an unprecedented scale (3,065 tests), leveraging phenome-

wide summary statistics from All of Us and the UK Biobank along with metabolite, microbiome,

and complex proteome GWASs. With the addition of Mendelian randomization, we have yielded

invaluable hypothesis-generating results for further validation, even if genetic variants do not

always meet the requisite instrumental variable assumptions for detecting causality. Five

metabolites showed nominally significant (p < 0.05) genetic correlation with endometriosis,

including serotonin which is known to be related to endometrial stromal cell decidualization[30]

but is also impacted by SSRIs like citalopram which may improve endometriosis symptoms[31]. We

have observed vertical pleiotropy supporting a potential causal relationship between

endometriosis and the reduction of the gut microbiome family *bifidobacteriaciae* (order

bifidobacteriales, class *actinobacteria*), which plays a role in estrogen regulation[32,33].

Results from across our multi-omic analyses underscore the potential role of R-spondin 3

(*RSPO3*) in endometriosis pathophysiology as a previously-characterized promotor of fibrotic

proliferation[34]. *RSPO3*, known to modulate risk of endometriosis[35], interacts with *WNT4* via

Frizzled (*FZD*) receptors, influencing the WNT/Ca2+ and WNT/β-catenin pathways[36]. Wnt protein

binding (GOMF) was a significant pathway in our gene set analyses, with five genes overlapping

with our biologically-implicated endometriosis gene set: *CTHRC1* (mSMR), *FZD6* (fibroblast-

eSMR), *PTPRO* (fibroblast-, ovary-, and whole blood-TWAS), *RECK* (fibroblast-sSMR), and

TRABD2A (mSMR). Specifically, within the Wnt protein family, evidence for *WNT4's* inverse

association with endometriosis is found in six endometrial cellular contexts, mSMR (positive

coefficient) and uterus- and ovary-TWAS (negative coefficient); methylation suppresses gene

expression. *WNT4* interacts with *ESR1* (Estrogen Receptor Alpha), key regulator of endometrial

cell proliferation and survival throughout the menstrual cycle[37]. *ESR1* was positively associated

with endometriosis in 19 endometrial cellular contexts, and mSMR returned causal CpG site

associations with intron-dependent effect directions. There were three stromal cellular contexts

in which the expressions of *RSPO3*, *WNT4*, and *ESR1* were significantly different depending on

endometriosis status. During the proliferative phase, all three were upregulated in

nondecidualized stromal cells from donors with endometriosis; in the early secretory phase,

WNT4 switched to being downregulated, and in the mid secretory phase, both *WNT4* and *RSPO3*

were diminished. Uncovering the interplay between these key genes throughout the menstrual

cycle will be essential for understanding endometriosis pathogenesis.

One hallmark of endometriotic lesions is cellular adhesion, the process by which cells

migrate and interact with the extracellular matrix[38,39]. An essential cytoskeletal protein which

plays a role in regulating adhesion and motility is vinculin (Vcn)[40]. We detected three

endometriosis-associated splicing events via sSMR and SWAS which support that expression of

an isoform of Vcn, metavinculin (MVcn, +exon 19), may reduce endometriosis risk. The AA

genotype at rs7896966 is associated with increased inclusion of exon 19[41], and our GWAS

identified that the AA genotype is also associated with decreased rates of endometriosis. It has

been demonstrated that MVcn expression contributes to fewer but larger focal adhesions per

cell[40] and that the inhibition of focal adhesion via FAK decreases the formation of endometriotic

lesions in mice[39]. While the GO gene set for focal adhesion assembly was not statistically

significant, there were four genes that overlapped with that pathway: *VCL* (sSMR)*, WNT4* (mSMR,

uterus- and ovary-TWAS)*, RHOD* (fibroblast-, uterus-, and ovary-eSMR)*,* and *KDR* (six cellular

contexts, mSMR, PWAS, and fibroblast-, uterus-, and ovary-TWAS). *RHOD* expression (codes for

the GTPase RhoD) had a negative causal relationship with endometriosis, which aligns with

previously published results that show that silencing RhoD leads to less efficient cell migration[42].

KDR exhibited mixed effect directions. Plasma PWAS along with endothelial cells and

decidualized stromal cells supported positive associations whereas TWAS and stromal matrix

metalloproteinase cells from the secretory phase indicated a negative association with *KDR*

expression. When KDR (a.k.a. vascular endothelial growth factor receptor 2; *VEGFR2*) is

stimulated by vascular endothelial growth factor (VEGF), it stimulates DNA synthesis and

promotes focal-adhesion-related cell migration[43]. Although more investigation is required to

precisely elucidate how the proteins in this pathway interact in the context of endometriosis, our

data clearly support the hypothesis that the regulation of focal adhesion may be a strong

candidate for therapeutic targets[39].

Given the strong interplay between endometriosis and regulation of the menstrual cycle,

it is important to take note of genetic and molecular signatures which may indicate hormonal

dysregulation. *GREB1* (codes for Growth Regulating Estrogen Receptor Binding 1) is a well-

characterized endometriosis-associated gene. We identified 23 cellular contexts in which *GREB1*

expression is elevated in cells from donors with endometriosis, mostly from the cells and nuclei

sampled during the secretory phase and from donors exposed to exogenous hormones. All five

associations between elevated *GREB1* and endometriosis under the immune lineage were in

nucleus types from donors on hormones. Since hormones are a common first-line treatment of

endometriosis symptoms[44], it is important to investigate how these medications interact with

immune cell types that contribute to an inflammatory response. We have also replicated

associations with known methylation and splice sites at the *GREB1* locus[45], while also expanding

upon the multi-omic molecular signature. *GREB1* has a truncated isoform, GREB1c, and we

demonstrate that splicing events in ovarian and uterine tissue associated with this isoform

increase risk of endometriosis while splicing events associated with the canonical isoform

(GREB1a) are associated with decreased disease risk. Importantly, *GREB1* was not associated with

endometriosis on the eQTL or pQTL levels, emphasizing that in order to promote mechanistic

hypotheses of endometriosis, we must continue to incorporate comprehensive layers of multi-

omics.

Despite the large sample size, heritability observed with GWAS (10-13%) still fails to

measure up to the broad sense heritability estimation from a twin study of 47%[9]. Rare variants,

structural variants, nonlinear effects, or gene-environment interactions might contribute to

endometriosis risk but remain undetected in our analyses. As we leveraged the GWAS results to

study other -omics from the central dogma and beyond, one limitation was that we lacked

individual-level data. The results captured by xWAS and xSMR relied on previously-trained *cis-*

xQTL models that are limited to capturing only genotype-driven molecular trait variability. This

may leave out complex genetic architecture (*i.e. trans*-xQTLs) or environmentally-driven

molecular signatures potentially relevant to our phenotype of interest[46]. While our innovative

and comprehensive *in silico* multi-omic approach yielded many testable hypotheses, we did not

perform any experimental functional validation. Furthermore, although our GWAS constitutes

the most diverse genetic study of endometriosis performed so far (32% non-European), we still

lacked the power to draw many meaningful conclusions in understudied populations. We want

to emphasize that the field should continue prioritizing the inclusion of diverse cohorts in genetic

studies.

In addition to replicating findings from previous studies, we uncovered new insights that

advanced our understanding of the genetic underpinnings of endometriosis. Our integrative

multi-omics approach, combining genomic data with single-cell analyses along with proteomic,

splice-omic, transcriptomic, methylomic, and RNA edit-omic tests, has biologically implicated 282

genes, providing unprecedented insights into the molecular mechanisms driving this chronic

condition. These findings lay a robust foundation for future functional studies to elucidate the

precise roles of identified genes and pathways in endometriosis pathogenesis. Moreover, our

results have important clinical implications, potentially informing the development of more

accurate diagnostic tools, personalized risk prediction models, and targeted therapeutic

interventions. As we move forward, this work emphasizes the critical importance of large-scale,

diverse genetic studies in unraveling the complexities of multifactorial diseases like

endometriosis, paving the way for improved patient outcomes and a deeper understanding of

women's health issues globally.

Methods

Phenotyping

Endometriosis diagnosis requires direct observation of lesions by laparoscopic surgery or

sometimes imaging (MRI/ultrasound). We can extract diagnoses from medical records via

diagnosis billing codes in the form of ontologies like the international classification of diseases

(ICD) or the systematized nomenclature of medicine (SNOMED). For the EHR-linked biobanks, we

used structured data to define the phenotypes. Cases for wide endometriosis (W) were any

women with a history of ICD-9 (617.*), ICD-10 (N80.*), or SNOMED codes for endometriosis. For

the wide phenotype excluding adenomyosis (Wex), women with a history of ICD-9 (617.0), ICD-

10 (N80.0), or SNOMED codes for uterine endometriosis were excluded from both cases and

controls. Our two narrow case definitions were procedure-confirmed and surgically-confirmed

(PCN and SCN). These narrow phenotypes were designed to capture confirmed cases and controls

of endometriosis based on procedure history including hysterectomies, laparoscopies and

ultrasounds. The list of procedure codes (CPT-4 or OPCS) for PCN included all the surgery codes

in SCN but added non-obstetric ultrasound codes to account for potential imaging diagnoses.

Each of the two narrow phenotypes was tested in two versions: cases versus all controls (PCN.v1

and SCN.v1) and cases versus confirmed controls (PCN.v2 and SCN.v2) where confirmed controls

were those who had history of the corresponding procedure codes for each phenotype with no

history of endometriosis diagnosis. For additional details on the phenotyping algorithms, see

Supplemental Appendix 1.

 Genotyping by Biobank

Most contributing biobanks genotyped several hundred thousand variants. After those data are

collected, then the rest of the genomic variants can be imputed probabilistically based on a

reference panel such as TOPMED. Some biobanks such as AOU used short read whole genome

sequencing (WGS) to gather their genomic data. The sequences from the short reads are aligned

and compared to the reference to produce variant calls. References and platform information for

each biobank's genotyping method and QC can be found in Supplementary Table 18.

Genetic Association Testing

Each contributing biobank performed ancestry-stratified association testing with up to six

phenotypes (W, Wex, PCN.v1, PCN.v2, SCN.v1, and SCN.v2), depending on whether they had at

least 50 cases for that phenotype and ancestry combination. Genetically-informed ancestry (GIA)

is defined based on genetic distance from subpopulations of a reference group such as the 1000

Genomes Project dataset[47] (1KG). Genetic distance is measured using a dimensionality reduction

technique such as principal component analysis (PCA). Ancestry is then assigned using a classifier

such as a mixture model or k-nearest neighbors. For references and methods used for assigning

GIA within each biobank, see Supplementary Table 19.

Contributing biobanks used linear mixed models to estimate the effect of each variant on

the six phenotypes. Tools implemented for these tests include SAIGE[48] and Regenie[49]. Association

tests were adjusted for principal components, age at EHR data collection, and any biobank-

specific batch variables (for example, collection site within eMERGE). For estimation of the null

models (SAIGE or Regenie step 1), variants were required to have a call rate of at least 95%, a

minor allele frequency of 0.01, and a Hardy-Weinberg p-value of at least 1×10^{-6}. For association

testing (SAIGE or Regenie step 2), variants were required to have a minor allele count of at least

20, and an imputation quality of at least 0.6. Individuals were included if their overall genotyping

rate was at least 95%. A summary of each biobank's exact covariates and QC procedures is in

Supplementary Table 20. We leveraged publicly-available FinnGen[50] summary statistics to

increase the sample size.

After biobank analyses were completed and collected, summary statistics were cleaned

and lifted into genome build hg38 as necessary. Then, inverse variance-weighted, fixed-effect

meta-analyses were performed using GWAMA (software for genome-wide association meta-

analysis)[51]. GWAMA adjusts each study based on its overall genomic inflation factor. Prior to

meta-analysis, input summary statistics were restricted to variants with a minor allele frequency

of at least 0.005 to ensure stability in the estimates.

To define significantly-associated loci, we started by applying the clumping function of

Plink 1.9[52] with the lead SNP p-value threshold set to 5×10^{-8}, the secondary SNP threshold set to

1, minimum R^2 of 0.1, and a window of 1000kb. 1KG was used as a linkage disequilibrium (LD)

reference, matching the whole dataset to the multi-ancestry meta-analyses and single-ancestry

subsets of the dataset to their respective meta-analyses. After the variant clumps were identified,

any clumps that were physically overlapping with one another were merged into loci. Then, we

tested if any loci were in LD with ($R^2 > 0.25$) or proximal to tag SNPs of the 39 autosomal lead

SNPs from the 2023 GWAS[6] to determine whether our hits were known or previously

unreported[16]. Each locus is labeled with its cytoband, but if the corresponding gene region was

statistically significant in the MAGMA, xSMR, or xWAS tests (described below), or if the GWAS

locus is in contact with a gene based on endometrial cell chromatin looping data[53], that gene

symbol was added to the locus label.

Estimation of Observed SNP Heritability and Genetic Correlation Amongst Endometriosis

GWASs

We estimated heritability with the LD-Score Regression tool, LDSC[54], for all single-ancestry

meta-analyses representing at least two thousand cases. LD scores were computed for HapMap

variants[55] from the respective super-population subgroups from 1KG for each ancestry-stratified

meta-analysis. We also estimated partitioned heritability[56] with variant annotation groups

coming from ENSEMBL regulatory features GRCh38.105[57] and uterus-specific regulatory features

from EpiMap[58]. We estimated cross-ancestry genetic correlation of our meta-analyses using

Popcorn[59]. Popcorn cross-population LD scores were derived from the same set of variants and

samples from 1KG as in LD score computation for LD score regression.

Statistical Fine-Mapping for Identification of Putative Causal Variants

The multi-ancestry sum of the single effects model (MESuSiE)[60] was used to identify

putative causal variants in each significant GWAS locus from the multi-ancestry meta-analyses.

For each locus, we extracted the single-ancestry summary statistics from that region in addition

to computing ancestry-specific LD matrices for AFR, AMR, EAS, EUR, and SAS. MESuSiE analyzes

whether causal variants are shared between ancestry groups by computing a posterior inclusion

probability (PIP) for each ancestry alone and for each combination of two or more ancestries.

SNPs with any PIP value greater than 0.5 are part of the credible set for that locus.

Variant-Set Enrichment for Identifying Enriched Gene Regions

MAGMA[61] was used to assess gene regions within the GWAS results for enrichment.

MAGMA uses a model based on multiple regression to test the association of a phenotype with

groups of variants. Testing groups of variants increases statistical power over the single-variant

GWAS tests performed[61]. We utilized gene region definitions from NCBI for human genome build

38, testing between 18,691-18,846 genes for each GWAS meta-analysis (MAGMA test counts and

p-value thresholds are available in Supplementary Table 21).

Phenome-Wide and Multi-Omic Genetic Correlation and Mendelian Randomization Tests

The AFR, EAS, and EUR wide phenotype meta-analyses were utilized for LDSC[54] genetic

correlation (GC) tests with phenome-wide GWAS summary statistics from AOU[62] and UKB (EUR-

only). In AOU, we tested for correlation with binary traits that had at least 2,000 cases

(medications and phecodeX phenotypes) and quantitative traits with at least 2,000 samples

overall (labs and biometric measurements), totaling 1,728 tests. From UKB, we utilized summary

statistics for diagnoses and survey variables, both binary and quantitative, with heritability

estimates for which the Z-score was at least 4 (527 studies)[63]. Summary statistics were also

obtained for 169 metabolites[64], 165 gut microbiome taxa[65], and 487 proteins[66] which we were

unable to map to one genomic location (mappable proteins were utilized in SMR described

below). Reference LD scores were computed from the corresponding 1KG superpopulation

groups across Hapmap variants[55]. For the larger-sample tests (AOU and UKBB phenome), genetic

correlation results with a p-value of < 0.05 were candidates for mendelian randomization, and

for the smaller tests (proteome and microbiome), traits with an h^2 p-value or rg p-value < 0.05

were nominated. Effect estimates were not available for the metabolites, so we could not

perform MR on those. Significant GC estimates were those that reached a p-value $< 1.63 \times 10^{-5}$

(correcting for 3,065 total tests).

To distinguish horizontal and vertical pleiotropy, we performed secondary mendelian

randomization (MR) tests on the 890 nominated traits using the MendelianRandomization R

package[67]. Several MR methods were utilized as a sensitivity analysis for the estimates: inverse-

variance weighted (IVW), debiased IVW, lasso-penalized IVW, weighted median, maximum

likelihood, and MR-Egger (random-effects). We tested in both directions: endometriosis causing

the test trait and vice-versa). Instrumental variables (IVs) were the genome-wide significant

variants from the HapMap-filtered[55] exposure summary statistics, and we used correlation

matrices calculated with PLINK 2.0[68] to adjust for the covariance between IVs. Significant causal

relationships were those for which the maximum p-value across methods was < 0.05, the

minimum p-value was $< 2.84 \times 10^{-5}$ (1,760 total bidirectional tests), all estimates were the same

direction, and that direction matched the direction of the genetic correlation estimate.

Integration with Single-Cell Data

Single cell data are rich resources for understanding the biology of diseases. A recently

published endometrial single cell atlas includes gene expression data for cells, nuclei, immune

cells, and immune nuclei, covering over 40 different cell types, three menstrual phases, and four

different endometrial pathologies[69]. We leveraged these data to compute single-cell disease-

relevance scores (scDRSs) based on the associated genes from GWAS, as computed by MAGMA.

Disease risk scores were computed and normalized using the scDRS software[70].

For each cell type and menstrual phase ("cellular context"), we computed the logistic

regression coefficient of the scDRS comparing cells from donors with and without endometriosis.

These regression models were adjusted for age; one source dataset only had an age range (18-

36), so we assigned age with a random uniform distribution to those cells. These regression

coefficients were used to prioritize cellular contexts (cell type – menstrual stage pairs). Significant

contexts were those which had a coefficient one-sided p-value of $< 0.05 / 240$ tests. For

prioritized contexts, we compared the expression of the top MAGMA genes (34 genes) between

case and control donors using t-tests to identify which genes were driving the distinguishing

effect of the scDRS. Significant t-tests were those with a p-value $< 0.05 / 1,190$ (34 genes x 35

significant contexts).

Multi-Omic Imputed Association Studies and Mendelian Randomization

We used GWAS summary statistics from the 11 meta-analyses to estimate the association

between endometriosis, transcript expression (TWAS), protein expression (PWAS), and intron

inclusion (SWAS). For TWAS and SWAS, we used precomputed eQTL and sQTL weights,

respectively, from the PredictDB data repository (http://predictdb.org/) which represented *cis-*

level associations in uterine tissue, ovarian tissue, whole blood, and cultured fibroblast cells. For

PWAS, we used whole blood pQTL models from *Schubert et al*[71] which are based on the

SOMAscan assay data measured in multi-ethnic Trans-omics for Precision Medicine (TOPMed)

Multi-omics pilot study. We used baseline models only (no covariates) which had a predictive

correlation (rho) of at least 0.1 and a z-score p-value threshold of 0.05, ensuring that the

association between the SNPs and protein expression was statistically significant. The xQTL

models along with the GWAS summary statistics were the input for summary-based PrediXcan

(S-PrediXcan)[72]. We used Bonferroni-correct p-value thresholds to identify statistically significant

associations for each tissue study. The alpha value was 0.05 and the numbers of tests for each

GWAS-tissue-QTL combination can be found in Supplementary Table S22. For labeling sQTLs,

GTEx provided a mapping from introns to transcripts.

Summary-Based Mendelian Randomization (SMR) is a publicly-available softare tool

which leverages uploaded GWAS summary statistics to detect pleiotropic associations between

molecular phenotypes as the exposure and a trait of interest as the outcome[73]. We tested all

combinations between the 11 GWASs and the following QTL datasets: GTEx eQTLs, sQTLs, and

edQTLs for ovary, uterus, whole blood, and fibroblast cells, plasma pQTLs from the FENLAND

study[66], McRae whole blood mQTLs[74], and Hatton blood mQTLs derived from EAS and EUR

populations[75]. The QTL was the exposure with endometriosis being the outcome. Significant

causal associations were identified as those with a p-value less than 0.05 / the number of tests

for each GWAS-tissue-dataset combination. Then, significantly heterogeneous results (HEIDI P <

0.05 / the number of significant tests) were discarded. The test counts and the corrected p-value

thresholds for the xSMR analyses are available in Supplemental Table S23.

Once we aggregated all genes resulting from MAGMA, xWAS, and xSMR, we performed basic

gene set testing using chi-squared statistics comparing our gene list to each pathway's list of

genes. The gene sets were from MSIGDB and included hallmark pathways, cell type signatures,

co-regulation pathways, and GO ontology pathways. The numbers of gene set tests corrected for

are available in Supplementary Table S24.

633   Data and Code Availability

All data required to recreate figures are available in supplemental tables S1-S24. GWAS summary

statistics will be uploaded to the GWAS catalog upon manuscript acceptance.

The availability of individual-level data varies by biobank. AOU, eMERGE, and UKBB are

available to researchers by application. The other biobanks (BBJ, BioVU, CCPM, FinnGen, GHI,

HUNT, Latvian National Biobank, MGBB, MVP, PMBB, and TWB) only allow access to institutional

researchers via their respective IRB protocols.

Code written and run by the coordinating center (PMBB) is available in this github

repository: https://github.com/Setia-Verma-Lab/guare_et_al_endometriosis_gwas_2025.

Acknowledgments

Research reported in this publication was supported by the Eunice Kennedy Shriver National

Institute of Child Health and Human Development of the National Institutes of Health under

award number R01HD110567.

We acknowledge the Penn Medicine BioBank (PMBB) for providing data and thank the

patient-participants of Penn Medicine who consented to participate in this research program.

We would also like to thank the Penn Medicine BioBank team and Regeneron Genetics Center

for providing genetic variant data for analysis. The PMBB is approved under IRB protocol# 813913

and supported by Perelman School of Medicine at University of Pennsylvania, a gift from the

Smilow family, and the National Center for Advancing Translational Sciences of the National

Institutes of Health under CTSA award number UL1TR001878.

This phase of the eMERGE Network was initiated and funded by the NHGRI through the

following grants: U01HG008657 (Group Health Cooperative/University of Washington);

U01HG008685 (Brigham and Women's Hospital); U01HG008672 (Vanderbilt University Medical

Center); U01HG008666 (Cincinnati Children's Hospital Medical Center); U01HG006379 (Mayo

Clinic); U01HG008679 (Geisinger Clinic); U01HG008680 (Columbia University Health Sciences);

U01HG008684 (Children's Hospital of Philadelphia); U01HG008673 (Northwestern University);

U01HG008701 (Vanderbilt University Medical Center serving as the Coordinating Center);

U01HG008676 (Partners Healthcare/Broad Institute); and U01HG008664 (Baylor College of

Medicine).

We gratefully acknowledge All of Us participants for their contributions, without whom

this research would not have been possible. We also thank the National Institutes of Health's All

of Us Research Program for making available the participant data examined in this study.

This research has been conducted using the Taiwan Biobank Resource. We thank all the

participants and investigators of the Taiwan Biobank. We thank the National Center for Genome

Medicine, Academia Sinica, Taiwan, for the technical support in the genotyping. We thank

National Core Facility for Biopharmaceuticals (NCFB, 112-2740-B-492-001) and National Center

for High-performance Computing (NCHC) of National Applied Research Laboratories (NARLabs)

of Taiwan for providing computational resources and storage resources. This study was

supported by the National Health Research Institutes (NP-109, 110, 111, 112, 113-PP-09),

Ministry of Science and Technology (MOST 109-2314-B-400-017, 110-2314-B-400-028-MY3), and

National Science and Technology Council (NSCT 113-2628-B-400-002), Taiwan.

The Trøndelag Health Study (The HUNT Study) is a collaboration between HUNT Research

Centre (Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science and

Technology), Trøndelag County Council, Central Norway Regional Health Authority, and the

Norwegian Institute of Public Health. The genotyping in HUNT was financed by the National

Institutes of Health; University of Michigan; the Research Council of Norway; the Liaison

Committee for Education, Research and Innovation in Central Norway; and the Joint Research

Committee between St Olavs hospital and the Faculty of Medicine and Health Sciences, NTNU.

The genetic investigations of the HUNT Study are a collaboration between researchers from the

HUNT Center for Molecular and Clinical Epidemiology (formerly known as the K.G. Jebsen Center

for Genetic Epidemiology as of August 1st 2023), NTNU, and the University of Michigan Medical

School and the University of Michigan School of Public Health. We thank HUNT participants for

donating their time, samples, and information to help others; clinicians and other employees at

Nord-Trøndelag Hospital Trust for their support and for contributing to data collection.

The authors thank Million Veteran Program (MVP) staff, researchers, and volunteers, who

have contributed to MVP, and especially participants who previously served their country in the

military and now generously agreed to enroll in the study.

Support for title page creation and format was provided by AuthorArranger, a tool

developed at the National Cancer Institute.

References

1. Christ, J. P. *et al.* Incidence, prevalence, and trends in endometriosis diagnosis: a United

States population-based study from 2006 to 2015. *American Journal of Obstetrics and*

Gynecology **225**, 500.e1-500.e9 (2021).

2. Agarwal, S. K. *et al.* Clinical diagnosis of endometriosis: a call to action. *American Journal of*

Obstetrics and Gynecology **220**, 354.e1-354.e12 (2019).

3. Fauconnier, A. & Chapron, C. Endometriosis and pelvic pain: epidemiological evidence of the

relationship and implications. *Human Reproduction Update* **11**, 595–606 (2005).

4.   Coccia, M. E., Nardone, L. & Rizzello, F. Endometriosis and Infertility: A Long-Life Approach to
Preserve Reproductive Integrity. *International Journal of Environmental Research and Public*
Health **19**, 6162 (2022).

5.   Sapkota, Y. *et al.* Meta-analysis identifies five novel loci associated with endometriosis
highlighting key genes involved in hormone metabolism. *Nat Commun* **8**, 15539 (2017).

6.   Rahmioglu, N. *et al.* The genetic basis of endometriosis and comorbidity with other pain and
inflammatory conditions. *Nat Genet* **55**, 423–436 (2023).

7.   Koller, D. *et al.* Multi-ancestry genome-wide association study of endometriosis and its
clinical manifestations in ~1.4 million women: translating gene discovery into pathogenic
mechanisms   and   therapeutic   targets.   2025.09.03.25335012   Preprint   at
https://doi.org/10.1101/2025.09.03.25335012 (2025).

8.   Fatumo, S. *et al.* A roadmap to increase diversity in genomic studies. *Nat Med* **28**, 243–250
(2022).

9.   Saha, R. *et al.* Heritability of endometriosis. *Fertility and Sterility* **104**, 947–952 (2015).

10.   Zhou, W. *et al.* Global Biobank Meta-analysis Initiative: Powering genetic discovery across
human disease. *Cell Genomics* **2**, 100192 (2022).

11.   Zhao, H. *et al.* Proteome-wide Mendelian randomization in global biobank meta-analysis
reveals multi-ancestry drug targets for common diseases. *Cell Genomics* **2**, (2022).

12.   Tsuo, K. *et al.* Multi-ancestry meta-analysis of asthma identifies novel associations and
highlights the value of increased power and diversity. *Cell Genomics* **2**, (2022).

13.   Faro, V. L. *et al.* Novel ancestry-specific primary open-angle glaucoma loci and shared biology
with vascular mechanisms and cell proliferation. *CR Med* **5**, (2024).

14. Verma, A. *et al.* The Penn Medicine BioBank: Towards a Genomics-Enabled Learning

Healthcare System to Accelerate Precision Medicine in a Diverse Population. *Journal of*

Personalized Medicine **12**, 1974 (2022).

15. Genomic data in the All of Us Research Program. *Nature* **627**, 340–346 (2024).

16. Verma, A. *et al.* Diversity and scale: Genetic architecture of 2068 traits in the VA Million

Veteran Program. *Science* **385**, eadj1182 (2024).

17. Nagai, A. *et al.* Overview of the BioBank Japan Project: Study design and profile. *Journal of*

Epidemiology **27**, S2–S8 (2017).

18. Pulley, J., Clayton, E., Bernard, G. R., Roden, D. M. & Masys, D. R. Principles of human subjects

protections applied in an opt-out, de-identified biobank. *Clin Transl Sci* **3**, 42–48 (2010).

19. Roden, D. *et al.* Development of a Large-Scale De-Identified DNA Biobank to Enable

Personalized Medicine. *Clinical Pharmacology & Therapeutics* **84**, 362–369 (2008).

20. Wiley, L. K. *et al.* Building a vertically integrated genomic learning health system: The biobank

at the Colorado Center for Personalized Medicine. *The American Journal of Human Genetics*

111, 11–23 (2024).

21. Gottesman, O. *et al.* The Electronic Medical Records and Genomics (eMERGE) Network: past,

present, and future. *Genet Med* **15**, 761–771 (2013).

22. David, S. P. *et al.* Personalized medicine in a community health system: the NorthShore

experience. *Front. Genet.* **14**, (2023).

23. Brumpton, B. M. *et al.* The HUNT study: A population-based cohort for genetic research. *Cell*

Genomics **2**, (2022).

24. Rovite, V. *et al.* Genome Database of the Latvian Population (LGDB): Design, Goals, and

Primary Results. *Journal of Epidemiology* **28**, 353–360 (2018).

25. Boutin, N. T. *et al.* The Evolution of a Large Biobank at Mass General Brigham. *Journal of*

Personalized Medicine **12**, 1323 (2022).

26. Fan, C.-T., Lin, J.-C. & Lee, C.-H. Taiwan Biobank: A Project Aiming to Aid Taiwan's Transition

into a Biomedical Island. *Pharmacogenomics* **9**, 235–246 (2008).

27. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature*

562, 203–209 (2018).

28. Katon, J. G., Plowden, T. C. & Marsh, E. E. Racial disparities in uterine fibroids and

endometriosis: a systematic review and application of social, structural, and political context.

Fertility and Sterility **119**, 355–363 (2023).

29. McKillop, M. Phenotyping Endometriosis from Observational Health Data. (Columbia

University, 2019). doi:10.7916/d8-1est-dh56.

30. Tian, J. *et al.* Dysregulation of endometrial stromal serotonin homeostasis leading to

abnormal phosphatidylcholine metabolism impairs decidualization in patients with recurrent

implantation failure. *Hum Reprod Open* **2024**, hoae042 (2024).

31. Hosseini, R., Mirzaei, S., Asgari, Z., Hajiloo, N. & Garrosi, L. Efficacy of adjunct therapy with

citalopram to improve health-related quality of life and associated symptoms in patients with

endometriosis: A randomized clinical trial. *Onkologia i Radioterapia* **18**, 1 (2024).

32. Uzuner, C., Mak, J., El-Assaad, F. & Condous, G. The bidirectional relationship between

endometriosis and microbiome. *Front. Endocrinol.* **14**, (2023).

33. Salliss, M. E., Farland, L. V., Mahnert, N. D. & Herbst-Kralovetz, M. M. The role of gut and

genital microbiota and the estrobolome in endometriosis, infertility and chronic pelvic pain.

Hum Reprod Update **28**, 92–131 (2022).

34. Zhang, M. *et al.* Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-

fibrosis treatment strategy for multiple organs. *PLoS One* **15**, e0229445 (2020).

35. Tao, T., Mo, X. & Zhao, L. Identifying novel potential drug targets for endometriosis via plasma

proteome screening. *Front Endocrinol (Lausanne)* **15**, 1416978 (2024).

36. Scholz, B. *et al.* Endothelial RSPO3 Controls Vascular Stability and Pruning through Non-

canonical WNT/Ca(2+)/NFAT Signaling. *Dev Cell* **36**, 79–93 (2016).

37. Gallagher, C. S. *et al.* Genome-wide association and epidemiological analyses reveal common

genetic origins between uterine leiomyomata and endometriosis. *Nat Commun* **10**, 4857

(2019).

38. Psilopatis, I. *et al.* The Hallmarks of Endometriosis. *Geburtshilfe und Frauenheilkunde* **84**,

555–563 (2024).

39. Nagai, T. *et al.* Focal Adhesion Kinase-Mediated Sequences, Including Cell Adhesion,

Inflammatory Response, and Fibrosis, as a Therapeutic Target in Endometriosis. *Reprod. Sci.*

27, 1400–1410 (2020).

40. Lee, H. T. *et al.* Vinculin and metavinculin exhibit distinct effects on focal adhesion properties,

cell migration, and mechanotransduction. *PLoS One* **14**, e0221962 (2019).

41. Garrido-Martín, D., Borsari, B., Calvo, M., Reverter, F. & Guigó, R. Identification and analysis

of splicing quantitative trait loci across multiple tissues in the human genome. *Nat Commun*

12, 727 (2021).

42. Blom, M., Reis, K., Heldin, J., Kreuger, J. & Aspenström, P. The atypical Rho GTPase RhoD is a

regulator of actin cytoskeleton dynamics and directed cell migration. *Experimental Cell*

Research **352**, 255–264 (2017).

43. Kanno, S. *et al.* Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF

effects in human vascular endothelial cells. *Oncogene* **19**, 2138–2146 (2000).

44. Brown, J. & Farquhar, C. An Overview of Treatments for Endometriosis. *JAMA* **313**, 296–297

(2015).

45. Mortlock, S. *et al.* Global endometrial DNA methylation analysis reveals insights into mQTL

regulation and associated endometriosis disease risk and endometrial function. *Commun Biol*

6, 780 (2023).

46. Mai, J., Lu, M., Gao, Q., Zeng, J. & Xiao, J. Transcriptome-wide association studies: recent

advances in methods, applications and available databases. *Commun Biol* **6**, 1–10 (2023).

47. An integrated map of genetic variation from 1,092 human genomes. *Nature* **491**, 56–65

(2012).

48. Zhou, W. *et al.* Efficiently controlling for case-control imbalance and sample relatedness in

large-scale genetic association studies. *Nat Genet* **50**, 1335–1341 (2018).

49. Mbatchou, J. *et al.* Computationally efficient whole-genome regression for quantitative and

binary traits. *Nat Genet* **53**, 1097–1103 (2021).

50. Kurki, M. I. *et al.* FinnGen provides genetic insights from a well-phenotyped isolated

population. *Nature* **613**, 508–518 (2023).

51. Mägi, R. & Morris, A. P. GWAMA: software for genome-wide association meta-analysis. *BMC*

Bioinformatics **11**, 288 (2010).

52. Purcell, S. *et al.* PLINK: A Tool Set for Whole-Genome Association and Population-Based

Linkage Analyses. *Am J Hum Genet* **81**, 559–575 (2007).

53. O'Mara, T. A., Spurdle, A. B. & Glubb, D. M. Analysis of Promoter-Associated Chromatin

Interactions Reveals Biologically Relevant Candidate Target Genes at Endometrial Cancer Risk

Loci. *Cancers (Basel)* **11**, 1440 (2019).

54. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from polygenicity in

genome-wide association studies. *Nat Genet* **47**, 291–295 (2015).

55. Manolio, T. A. & Collins, F. S. The HapMap and Genome-Wide Association Studies in Diagnosis

and Therapy*. *Annual Review of Medicine* **60**, 443–456 (2009).

56. Finucane, H. K. *et al.* Partitioning heritability by functional annotation using genome-wide

association summary statistics. *Nat Genet* **47**, 1228–1235 (2015).

57. Harrison, P. W. *et al.* Ensembl 2024. *Nucleic Acids Research* **52**, D891–D899 (2024).

58. Boix, C. A., James, B. T., Park, Y. P., Meuleman, W. & Kellis, M. Regulatory genomic circuitry

of human disease loci by integrative epigenomics. *Nature* **590**, 300–307 (2021).

59. Brown, B. C., Ye, C. J., Price, A. L. & Zaitlen, N. Transethnic Genetic-Correlation Estimates from

Summary Statistics. *The American Journal of Human Genetics* **99**, 76–88 (2016).

60. Gao, B. & Zhou, X. MESuSiE enables scalable and powerful multi-ancestry fine-mapping of

causal variants in genome-wide association studies. *Nat Genet* **56**, 170–179 (2024).

61. Leeuw, C. A. de, Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: Generalized Gene-Set

Analysis of GWAS Data. *PLOS Computational Biology* **11**, e1004219 (2015).

62. Overview of the All by All tables available on the All of Us Researcher Workbench. *User*

Support https://support.researchallofus.org/hc/en-us/articles/27049847988884-Overview-

of-the-All-by-All-tables-available-on-the-All-of-Us-Researcher-Workbench (2025).

63. Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and traits. *Nat*

Genet **47**, 1236–1241 (2015).

64. Hysi, P. G. *et al.* Metabolome Genome-Wide Association Study Identifies 74 Novel Genomic

Regions Influencing Plasma Metabolites Levels. *Metabolites* **12**, 61 (2022).

65. Kurilshikov, A. *et al.* Large-scale association analyses identify host factors influencing human

gut microbiome composition. *Nat Genet* **53**, 156–165 (2021).

66. Pietzner, M. *et al.* Mapping the proteo-genomic convergence of human diseases. *Science* **374**,

eabj1541 (2021).

67. Patel, A. *et al.* MendelianRandomization v0.9.0: updates to an R package for performing

Mendelian randomization analyses using summarized data. *Wellcome Open Res* **8**, 449

(2023).

68. Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer

datasets. *GigaScience* **4**, s13742-015-0047–8 (2015).

69. Marečková, M. *et al.* An integrated single-cell reference atlas of the human endometrium.

Nat Genet **56**, 1925–1937 (2024).

70. Zhang, M. J. *et al.* Polygenic enrichment distinguishes disease associations of individual cells

in single-cell RNA-seq data. *Nat Genet* **54**, 1572–1580 (2022).

71. Schubert, R. *et al.* Protein prediction for trait mapping in diverse populations. *PLOS ONE* **17**,

e0264341 (2022).

72. Gamazon, E. R. *et al.* A gene-based association method for mapping traits using reference

transcriptome data. *Nat Genet* **47**, 1091–1098 (2015).

73. Zhu, Z. *et al.* Integration of summary data from GWAS and eQTL studies predicts complex

trait gene targets. *Nat Genet* **48**, 481–487 (2016).

74. McRae, A. F. *et al.* Identification of 55,000 Replicated DNA Methylation QTL. *Sci Rep* **8**, 17605

(2018).

75. Hatton, A. A. *et al.* Genetic control of DNA methylation is largely shared across European and

East Asian populations. *Nat Commun* **15**, 2713 (2024).

860